Almac Announces Launch of Bioinformatics Consultancy
Almac’s
Diagnostics business unit today announced the launch of its Bioinformatics Consultancy service.
Almac’s Bioinformatics consultancy supports discovery and development of biomarkers as well as enabling an in-depth understanding of biology by partnering with customers in the pharmaceutical, biotech, and diagnostics setting from the initial study design through to the interpretation of data results.
The consultancy service offers a range of customizable bioinformatics and biostatistics solutions which include; Biomarker Discovery and Development, Exploratory Analysis, Mechanistic, and Functional Analysis, Traditional and Next Generation Sequencing Data Analysis, Biostatistics, and Data Integration.
The solutions are delivered through a large bioinformatics team from a wide range of disciplines including biology, medicine, mathematics, and biostatistics. In addition the team also has experience in molecular and cell biology, drug discovery and development, and diagnostic product development.
Professor Paul Harkin, President and Managing Director of Almac’s Diagnostic business unit said:
Bioinformatics has always been a key strength for us in Almac. Over the years we have built up a world class team of bioinformaticians and biostatisticians. This team has provided invaluable support for both our internal research and our external work. The launch of the full bioinformatics consultancy business is the next logical step in enabling our customer’s to access this important resource”.
Driving Diversity with the Integrated Research Model
October 16th 2024Ashley Moultrie, CCRP, senior director, DEI & community engagement, Javara discusses current trends and challenges with achieving greater diversity in clinical trials, how integrated research organizations are bringing care directly to patients, and more.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
The Rise of Predictive Engagement Tools in Clinical Trials
November 22nd 2024Patient attrition can be a significant barrier to the success of a randomized controlled trial (RCT). Today, with the help of AI-powered predictive engagement tools, clinical study managers are finding ways to proactively reduce attrition rates in RCTs, and increase the effectiveness of their trial. In this guide, we look at the role AI-powered patient engagement tools play in clinical research, from the problems they’re being used to solve to the areas and indications in which they’re being deployed.
